Urologia

Phase II Randomized Study Comparing Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy (IGRT) With Urethral Sparing for Intermediate Risk Prostate Cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	NCT Number
Fundação Champalimaud Centro Champalimaud Avenida de Brasília 1400-038 Lisboa - Portugal	Prof. Doutor Carlo Greco	Recrutamento	NCT02570919

A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital CUF Descobertas Rua Mário Botas 1998- 018 Lisboa - Portugal	Dr. António Quintela	Recrutamento	2018-001967-22
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dr. Jorge Oliveira	Recrutamento	2018-001967-22

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital Lusíadas Lisboa Rua Abílio Mendes 1500-468 Lisboa - Portugal	Dr. Paulo Cortes	Recrutamento	2017-003344-21
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Filipa Carneiro	Recrutamento	2017-003344-21

A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital Lusíadas Lisboa Rua Abílio Mendes 1500-468 Lisboa - Portugal	Dr. Paulo Cortes	Recrutamento	2017-002932-18

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib in Combination With Physician's Choice of Enzalutamide or Abiraterone Acetate/Prednisone in Patients With DNA Damage Repair Deficiencies and Metastatic Castration-Resistant Prostate Cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Fundação Champalimaud Av. Brasília 1400-038 Lisboa - Portugal	Dr. Nuno Vau	Recrutamento	2017-003295-31
Hospital de Braga Sete Fontes – São Victor 4710-243 Braga - Portugal	Dr. Estevão Lima	Recrutamento	2017-003295-31